Terns Pharmaceuticals Announces Major Stock Offering

Terns Pharmaceuticals ( (TERN) ) just unveiled an update.

On December 9, 2025, Terns Pharmaceuticals announced an underwritten public offering of 16,250,000 shares of common stock at $40.00 per share, with an option for underwriters to purchase an additional 2,437,500 shares. The offering, expected to close on December 11, 2025, aims to raise approximately $705.8 million in net proceeds, which will be used to fund research, clinical trials, and potential commercial launch preparations for TERN-701, among other corporate purposes. This move is expected to bolster Terns’ financial position, enabling it to fund operations into 2031, and strengthen its market positioning in the oncology sector.

The most recent analyst rating on (TERN) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Terns Pharmaceuticals stock, see the TERN Stock Forecast page.

Spark’s Take on TERN Stock

According to Spark, TipRanks’ AI Analyst, TERN is a Neutral.

Terns Pharmaceuticals’ overall score reflects significant financial challenges due to lack of revenue and ongoing losses. Despite strong cash reserves and low debt, the company faces high risk due to persistent cash burn. The stock’s technical indicators suggest a bearish trend, and its negative valuation factors further hinder attractiveness. However, the new CFO appointment could enhance strategic financial management, offering a glimmer of potential improvement.

To see Spark’s full report on TERN stock, click here.

More about Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage oncology company focused on developing innovative medicines by reimagining known biology. Its lead program, TERN-701, is a selective BCR-ABL inhibitor aimed at improving the treatment of chronic myeloid leukemia (CML).

Average Trading Volume: 3,389,631

Technical Sentiment Signal: Buy

Current Market Cap: $3.83B

For detailed information about TERN stock, go to TipRanks’ Stock Analysis page.